恆投證券(01476.HK)擬發行科技創新債及短期公司債 涉資最多44億人幣
恆投證券(01476.HK)宣佈,爲拓寬融資管道,優化債務結構,滿足業務發展的需要,擬於中國境內發行科技創新公司債券及科技創新次級債券,兩類債券合稱爲「科創債」,發行總額不超過10億元人民幣,採用固定利率計息,期限爲三年,所得資金逾70%將用於專項支持科技創新領域業務,餘下用作補充流動資金及償債。發行對象爲不超過200名符合規定的專業投資者。
公司並計劃發行短期公司債券,期限不超過1年,規模不超過34億元人民幣,所募集資金將用於償還一年內到期債務及補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.